Pharma Exclusives Pressreleases
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
Wednesday, December 11, 2024Arvinas Inc and Pfizer Inc announced preliminary data from the ongoing Phase b portion of the TACTIVEU substudy of vepdegestrant in combination with abemaciclib among patients with locally advanced or metastatic estrogen receptor positive ERhuman epi...
New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
Tuesday, December 10, 2024Roche announced today that new and updated data from its industryleading CDxCD Tcellengaging bispecific antibody programme were presented at the th American Society of Hematology ASH Annual Meeting Exposition December With more than bispecific an...
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Tuesday, December 10, 2024Artelo Biosciences Inc a clinicalstage pharmaceutical company focused on modulating lipidsignaling pathways to develop treatments for people living with cancer pain dermatologic and neurological conditions today announced the presentation of prelimin...
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
Monday, December 09, 2024Roche announced today data from a fiveyear followup of the pivotal phase III POLARIX study evaluating Polivy polatuzumab vedotin in combination with MabTheraRituxan rituximab cyclophosphamide doxorubicin and prednisone RCHP in people with untreated d...
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
Wednesday, December 04, 2024Teva Pharmaceutical Industries Ltd presented positive data from its Phase SPACE study evaluating the efficacy and safety of AJOVY fremanezumab for the prevention of episodic migraine in children and adolescent patients aged years The trial showed s...
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
Tuesday, December 03, 2024Hansa Biopharma Hansa and Genethon a pioneer and a leader in gene therapy research and development for rare genetic diseases today announced initiation of GNTIDES a Phase trial in patients with CriglerNajjar syndrome with preexisting antibodies agai...
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Tuesday, December 03, 2024Ipsen and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX BMX is a bispecific antibody that engages and activates a subset of cytotoxic T cells called MucosalAssociated Invariant T cells MAIT cells and targets...
